Recognizing the role and potential of IL-6 in tumors, we collected blood specimens from 141 advanced ESCC patients before treating them with PD-1 inhibitors at our institution, and further analysis found that PFS and OS were lower in those with greater baseline IL-6 levels. The gene discussed is IL6; the disease is esophageal squamous cell carcinoma.